Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib versus niraparib + bevacizumab in newly diagnosed advanced ovarian cancer
2024-516066-11-00Phase 3Authorised
- Sponsor
- AGO Research
- Start
- Aug 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of niraparib, bevacizumab, carboplatin and paclitaxel in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by AGO Research. Primary endpoint: Progression-free survival. Planned start Aug 2022; status: authorised.
02
Drugs
niraparibbevacizumabcarboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-516066-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516066-11-00.